Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2‐methoxyestradiol
Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), William D. Figg(National Institutes of Health), Jürgen Venitz(National Cancer Institute), Alex Sparreboom(The Ohio State University), Xia Xu(Science Applications International Corporation (United States)), William L. Dahut(National Cancer Institute), Timothy D. Veenstra(Leidos (United States))
Cited by 38
Related Papers
Cremophor EL
|European Journal of Cancer|2001|1.6k
The Human Plasma Proteome
|Molecular & Cellular Proteomics|2004|1k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|973
DIETARY PHYTOESTROGENS
|Annual Review of Nutrition|1997|832
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766